MondegarAI
CAXTON CORP

Q1 2025 · 13F-HR

CAXTON CORPholdings as filed

Filed 2025-05-15 · accession 0000919574-25-003127

$5.1M
Reported value
12
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
76200L309RZLTREZOLUTE INC$3.8M75.3%1,318,967CommonSOLE
78463V107GLDSPDR GOLD TR$374,1017.36%1,298CommonSOLE
084670702BRK/BBERKSHIRE HATHAWAY INC DEL$248,8164.90%467CommonSOLE
60255C885BRD1EURMIND MEDICINE MINDMED INC$199,3273.92%34,073CommonSOLE
055477103BCAXBICARA THERAPEUTICS INC$142,5622.81%10,941CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$82,5841.63%43,465CommonSOLE
52886X107LXEOLEXEO THERAPEUTICS INC$61,9431.22%17,851CommonSOLE
501976104KYTXKYVERNA THERAPEUTICS INC$44,3540.87%22,981CommonSOLE
14147L108CRDFCARDIFF ONCOLOGY INC$41,7210.82%13,287CommonSOLE
45719W205IKTINHIBIKASE THERAPEUTICS INC$35,9010.71%16,393CommonSOLE
007002108TORCEURADICET BIO INC$13,2030.26%17,488CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$11,2630.22%18,403CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.